NCT03730064

Brain Imaging to Understand the Role of Inflammation in N-Acetyl Cysteine (NAC) Treatment of Bipolar Depression

Neuroinflammation as a Novel Target to Treat Bipolar Depression: A Pilot PET Study With [11C]PBR-28 and N-Acetyl Cysteine (NAC) Antidepressant Treatment

• Status: Completed
• Phase: EARLY_Phase 1
• Study type: Interventional
• Enrollment: 3 (actual)
• Sponsor: Martin Lan · Academic / Other
• Sex: All
• Age: 18 Years – 60 Years
• Healthy volunteers: Not accepted

Summary

We are trying to understand what causes bipolar disorder and how medications treat bipolar depression. Particularly, we are looking at the importance of inflammation in the process. If you participate, you will have two different brain scans (MRI and PET scan). You will also have an experimental treatment for your depression named N-acetyl cysteine (NAC). The study is funded by the Columbia University Irving Institute to improve the treatment of bipolar disorder. Please contact us if you are interested in participating. Up to $600 in compensation if you are eligible and choose to participate. Up to 6 months of treatment for depression at no cost to you.

Conditions

• Bipolar Disorder
• Depression

Interventions

Type	Name	Description
DRUG	N-acetyl cysteine (NAC)	Experimental medication with N-acetyl cysteine (NAC) for six weeks

Timeline

• Start date: 2018-11-01
• Primary completion: 2021-03-01
• Completion: 2021-03-01
• First posted: 2018-11-05
• Last updated: 2021-08-05

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study